Mitochondria-Targeted Protective Compounds in Parkinson’s and Alzheimer’s Diseases
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Mitochondria are cytoplasmic organelles that regulate both metabolic and apoptotic signaling pathways; their most highlighted functions include cellular energy generation in the form of adenosine triphosphate (ATP), regulation of cellular calcium homeostasis, balance between ROS production and detoxification, mediation of apoptosis cell death, and synthesis and metabolism of various key molecules. Consistent evidence suggests that mitochondrial failure is associated with early events in the pathogenesis of ageing-related neurodegenerative disorders including Parkinson’s disease and Alzheimer’s disease. Mitochondria-targeted protective compounds that prevent or minimize mitochondrial dysfunction constitute potential therapeutic strategies in the prevention and treatment of these central nervous system diseases. This paper provides an overview of the involvement of mitochondrial dysfunction in Parkinson’s and Alzheimer’s diseases, with particular attention to in vitro and in vivo studies on promising endogenous and exogenous mitochondria-targeted protective compounds.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2016 Alzheimer's disease facts and figures
Alzheimer's Association (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.03.001 · Cited by 5,069
Chronic Parkinsonism in Humans Due to a Product of Meperidine-Analog Synthesis
Langston, J. W., Ballard, P., Tetrud, J. W., & Irwin, I. (1983) · Science · doi:10.1126/science.6823561 · Cited by 4,914
Epidemiology of Parkinson's disease
de Lau, L. M., & Breteler, M. M. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70471-9 · Cited by 4,110
Forecasting the global burden of Alzheimer's disease
Brookmeyer, R., Johnson, E., Ziegler‐Graham, K., & Arrighi, H. M. (2007) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2007.04.381 · Cited by 3,370
Neuropathological alterations in Alzheimer disease
Serrano-Pozo, A., Frosch, M. P., Masliah, E., & Hyman, B. T. (2011) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006189 · Cited by 3,345
Pathways towards and Away from Alzheimer’s Disease
Mattson, M. P. (2004) · Nature · doi:10.1038/nature02621 · Cited by 3,052
Mitochondrial Complex I Deficiency in Parkinson's Disease
Schapira, A. H. V., Cooper, J. M., Dexter, D., Clark, J. B., Jenner, P., & Marsden, C. D. (1990) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1990.tb02325.x · Cited by 2,283 · cited 1×
“Many lines of evidence have further demonstrated complex I deficiency or impairment in the cortical brain tissue, frontal cortex, striatum, skeletal muscle, and platelets of patients with Parkinson’s disease [40, 45, 46].”
BackgroundThe prevalence of Parkinson's disease: a systematic review and meta-analysis
Pringsheim, T., Jette, N., Frolkis, A., & Steeves, T. D. L. (2014) · Movement Disorders · doi:10.1002/mds.25945 · Cited by 2,188
The Role of Oxidative Stress in Parkinson's Disease
Dias, V., Junn, E., & Mouradian, M. M. (2013) · Journal of Parkinson’s Disease · doi:10.3233/jpd-130230 · Cited by 1,845
-Synuclein in Parkinson's Disease
Stefanis, L. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a009399 · Cited by 1,446
Kalaria, R. N., Maestre, G. E., Arizaga, R., Friedland, R. P., Galasko, D., Hall, K., Luchsinger, J. A., Ogunniyi, A., Perry, E. K., Potocnik, F., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70169-8 · Cited by 1,233
Impaired Balance of Mitochondrial Fission and Fusion in Alzheimer's Disease
Wang, X., Su, B., Lee, H.-G., Li, X., Perry, G., Smith, M. A., & Zhu, X. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.1357-09.2009 · Cited by 1,224
Ramirez, A., Heimbach, A., Gründemann, J., Stiller, B., Hampshire, D., Cid, L. P., Goebel, I., Mubaidin, A. F., Wriekat, A.-L., Roeper, J., et al. (2006) · Nature Genetics · doi:10.1038/ng1884 · Cited by 1,208
Manczak, M., Anekonda, T. S., Henson, E., Park, B. S., Quinn, J., & Reddy, P. H. (2006) · Human Molecular Genetics · doi:10.1093/hmg/ddl066 · Cited by 1,104
Parkinson’s disease: genetics and pathogenesis
Shulman, J. M., De Jager, P. L., & Feany, M. B. (2011) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130242 · Cited by 801 · cited 2×
“Parkinson’s disease is a chronic progressive disorder characterized pathologically by the loss of dopaminergic neurons located in the substantia nigra pars compacta, and, to a lesser extent, in putamen, caudate, and globus pallidus and by the formation of intracellular protein inclusions of mainly alpha-synuclein (nam…”
BackgroundDevi, L., Prabhu, B. M., Galati, D. F., Avadhani, N. G., & Anandatheerthavarada, H. K. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1469-06.2006 · Cited by 792 · cited 1×
“The higher the level of arrestedmitochondrial APP, the worse the mitochondrial dysfunction [155].”
BackgroundMitochondrial Defects and Oxidative Stress in Alzheimer Disease and Parkinson Disease
Yan, M. H., Wang, X., & Zhu, X. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.11.014 · Cited by 718 · cited 1×
“Oxidative Medicine and Cellular Longevity 13 During the last two decades, consistent evidences have proposed oxidative stress as a crucial pathogenic mechanism underlying AD [139].”
BackgroundAnimal models of Alzheimer's disease and frontotemporal dementia
Götz, J., & Ittner, L. M. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2420 · Cited by 676 · cited 1×
“Concerning AD models of study, unfortunately, there is no animal model so far that replicates all the major aspects of AD pathology and symptoms, andmodels based on postulated disease pathways are widely used to explore biological targets [167].”
BackgroundCalkins, M. J., Manczak, M., Mao, P., Shirendeb, U., & Reddy, P. H. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr381 · Cited by 646
Mitochondria-targeted antioxidants protect against amyloid-β toxicity in Alzheimer's disease neurons
Manczak, M., Mao, P., Calkins, M. J., Cornea, A., Reddy, A. P., Murphy, M. P., Szeto, H. H., Park, B., & Reddy, P. H. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-100564 · Cited by 469
Hauptmann, S., Scherping, I., Dröse, S., Brandt, U., Schulz, K. L., Jendrach, M., Leuner, K., Eckert, A., & Müller, W. E. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.12.005 · Cited by 469
Alzheimer Disease and Oxidative Stress
Perry, G., Cash, A. D., & Smith, M. A. (2002) · BioMed Research International · doi:10.1155/s1110724302203010 · Cited by 455 · cited 1×
“As a result of OS, accumulated oxidative damage to lipids, proteins, and nucleic acids in postmortem studies of brains of patients with AD has been identified: advanced glycation end-products (AGEs), advanced lipid peroxidation endproducts, nucleic acid oxidation, carbonyl-modified neurofilament protein, and free carb…”
BackgroundHaas, R. H., Nasirian, F., Nakano, K., Ward, D., Pay, M., Hill, R., & Shults, C. W. (1995) · Annals of Neurology · doi:10.1002/ana.410370604 · Cited by 435
McManus, M. J., Murphy, M. P., & Franklin, J. L. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.0552-11.2011 · Cited by 432 · cited 2×
“Other models even express more mutations, such as 3xTg-ADmousemodel that includes three mutant human genes: APPswe, presenilin-1 (PS1M146V), and tau protein (tau P301L); in this model, MMP loss and higher caspases 3 and 9 activations are observed [171].”
BackgroundReddy, P. H., Tripathi, R., Troung, Q., Tirumala, K., Reddy, T. P., Anekonda, V., Shirendeb, U. P., Calkins, M. J., Reddy, A. P., Mao, P., et al. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.10.011 · Cited by 394 · cited 2×
“Neurodegeneration and synaptic degradation in AD are primarily mediated by defective mitochondrial biogenesis and axonal transport of mitochondria [162].”
BackgroundMitochondria-targeted peptide antioxidants: Novel neuroprotective agents
Szeto, H. H. (2006) · The AAPS Journal · doi:10.1208/aapsj080362 · Cited by 332 · cited 1×
“Recently, Szeto developed a series of small, cell-permeable antioxidant peptides (SS peptides) that are known to protect mitochondria from oxidative damage [222].”
BackgroundParkinson’s disease risks associated with dietary iron, manganese, and other nutrient intakes
Powers, K. M., Smith-Weller, T., Franklin, G. M., Longstreth, W. T., Swanson, P. D., & Checkoway, H. (2003) · Neurology · doi:10.1212/01.wnl.0000068021.13945.7f · Cited by 268
The role of the LRRK2 gene in Parkinsonism
Li, J.-Q., Tan, L., & Yu, J.-T. (2014) · Molecular Neurodegeneration · doi:10.1186/1750-1326-9-47 · Cited by 249 · cited 1×
“Focusing on this last pathogenic mechanism, mutations in LRRK2 cause mitochondrial fragmentation and a downregulation in mitochondrial homeostasis (reduction in mitochondrial membrane potential and ATP production) [37, 38].”
BackgroundFunctional mitochondria are required for amyloid β‐mediated neurotoxicity
Cardoso, S. M., Santos, S., Swerdlow, R. H., & Oliveira, C. R. (2001) · The FASEB Journal · doi:10.1096/fj.00-0561fje · Cited by 203 · cited 1×
“In support of this, it has been shown that cells depleted of endogenousmDNA lacking functional electron transport chains (ETC) are resistant to Aβ toxicity [149]; also, a reduced respiratory capacity and low cytochrome oxidase activity were found in isolated mitochondria exposed to Aβ [150, 151]; transgenic mice expre…”
BackgroundThe role of dopamine oxidation in mitochondrial dysfunction: implications for Parkinson’s disease
Hastings, T. G. (2009) · Journal of Bioenergetics and Biomembranes · doi:10.1007/s10863-009-9257-z · Cited by 199 · cited 1×
“In vitro experimental researches on neuronal cell types and isolated brain mitochondria and in vivo studies using different animal models and postmortem brain studies in Parkinson’s disease have demonstrated that dopamine oxidation and reactive dopamine quinone oxidation products inducemitochondrial respiration uncoup…”
Backgroundβ‐Amyloid fragment 25–35 selectively decreases complex IV activity in isolated mitochondria
Canevari, L., Clark, J. B., & Bates, T. E. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)01028-5 · Cited by 196
Turunc Bayrakdar, E., Uyanikgil, Y., Kanit, L., Koylu, E., & Yalcin, A. (2014) · Free Radical Research · doi:10.3109/10715762.2013.857018 · Cited by 169
Mitochondrial contact sites: their role in energy metabolism and apoptosis
Brdiczka, D. G., Zorov, D. B., & Sheu, S.-S. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2005.09.007 · Cited by 150 · cited 1×
“, superoxide anion (O 2 ) and the highly reactive hydroxyl radical (OH)), mediation of the process of programmed cell death (apoptosis), and synthesis and metabolism of endogenous compounds such as steroids, heme groups, and fatty acids [5].”
BackgroundMitochondrial function impairment induced by amyloid β-peptide on PC12 cells
Pereira, C., Santos, M. S., & Oliveira, C. (1998) · NeuroReport · doi:10.1097/00001756-199806010-00015 · Cited by 115
Ergothioneine rescues PC12 cells from β-amyloid-induced apoptotic death
Jang, J.-H., Aruoma, O. I., Jen, L.-S., Chung, H. Y., & Surh, Y.-J. (2004) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2003.11.005 · Cited by 112
Crude caffeine reduces memory impairment and amyloid β1–42 levels in an Alzheimer’s mouse model
Chu, Y.-F., Chang, W.-H., Black, R. M., Liu, J.-R., Sompol, P., Chen, Y., Wei, H., Zhao, Q., & Cheng, I. H. (2012) · Food Chemistry · doi:10.1016/j.foodchem.2012.04.148 · Cited by 106
Barros Silva, R., Santos, N. A. G., Martins, N. M., Ferreira, D. A. S., Barbosa, F., Oliveira Souza, V. C., Kinoshita, Â., Baffa, O., Del-Bel, E., & Santos, A. C. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2012.12.041 · Cited by 88 · cited 1×
“The caffeic acid phenethyl ester inhibited 6-OHDA-induced mitochondrial apoptotic pathway in in vitro and in vivomodels [85, 86].”
MethodTargeting coenzyme Q derivatives to mitochondria
Smith, R. A. J., Kelso, G. F., James, A. M., & Murphy, M. P. (2004) · Methods in Enzymology · doi:10.1016/s0076-6879(04)82003-2 · Cited by 87
Lee, S. H., Kim, K.-R., Ryu, S.-Y., Son, S., Hong, H. S., Mook-Jung, I., Lee, S.-H., & Ho, W.-K. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.0465-12.2012 · Cited by 86
Zhang, W., Hu, C., Yang, Z., Zhou, Q., Peng, D., Yuan, X., Lv, Z., Pang, S., Jiang, W., Yang, C., et al. (2014) · Neural Regeneration Research · doi:10.4103/1673-5374.130117 · Cited by 36 · cited 1×
“Most of the cases of AD are believed to be “sporadic” and their causal factors are still unknown for the vast majority of patients; on the other hand, genetic factors cause about 2% of all AD cases and include mutations in APP (Aβ protein precursor), presenilin-1 and presenilin-2 genes, and polymorphisms in apolipopro…”
Background
Cited by
Mitophagy and Alzheimer’s Disease: Cellular and Molecular Mechanisms
Kerr, J. S., Adriaanse, B. A., Greig, N. H., Mattson, M. P., Cader, M. Z., Bohr, V. A., & Fang, E. F. (2017) · Trends in Neurosciences · doi:10.1016/j.tins.2017.01.002 · Cited by 870
Parkinson's disease: Mechanisms, translational models and management strategies
Raza, C., Anjum, R., & Shakeel, N. U. A. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.03.057 · Cited by 603
Inhibitory Effect of Astaxanthin on Oxidative Stress-Induced Mitochondrial Dysfunction-A Mini-Review
Kim, S. H., & Kim, H. (2018) · Nutrients · doi:10.3390/nu10091137 · Cited by 290
Walecha, V., & Luthra, P. M. (2025) · Neurochemical Research · doi:10.1007/s11064-025-04559-9 · Cited by 12
1,5-Benzodiazepin-2(3H)-ones: In Vitro Evaluation as Antiparkinsonian Agents
Ortíz de Zárate, A., Pérez-Torralba, M., Bonet Isidro, I., López, C., Claramunt, R. M., Martínez-Casanova, D., Sánchez-Vera, I., Jiménez-González, J., & Lavandera, J. L. (2021) · Antioxidants · doi:10.3390/antiox10101584 · Cited by 11
“The beneficial effects of antioxidants have been demonstrated in in vitro and in vivo models of PD [29,41,42].”
Background
Metadata
- Authors
- Fernández-Moriano, C., González-Burgos, E., & Gómez-Serranillos, M. P.
- Venue
- Oxidative Medicine and Cellular Longevity
- Publisher
- Wiley
- Published
- 2015
- Volume
- 2015
- Pages
- 1-30
- ISSN
- 1942-0994 (ISSN-L)
- 1942-0900
- OpenAlex
- W2071299784
- Cited by
- 94
- References
- 40
- FWCI
- 4.89
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.